01 Shift toward Integrated AI-powered Viscoelastic Analytics AI-integrated viscoelastic analytics presents a key point-of-care coagulation testing devices market trend. AI-integrated analytics are increasingly being adopted in trauma centers and cardiac surgery units to predict intraoperative bleeding risks in real time. These platforms combine machine learning algorithms with thromboelastographic data to identify abnormal clot formation patterns before critical deterioration occurs. Growing integration of AI-assisted coagulation interpretation with surgical workflow platforms is improving transfusion management efficiency, perioperative decision-making, and rapid hemostatic assessment across high-acuity healthcare environments.
02 Shift toward Cartridge-based Microfluidic Coagulation Platforms The shift toward compact cartridge-based microfluidic coagulation analyzers is a major market trend in intensive care and emergency medicine due to their ability to deliver rapid clotting assessments using minimal blood volumes. These systems integrate lab-on-chip technology with automated digital calibration to reduce operator variability during bedside testing. Companies such as Microvisk Technologies are advancing microfluidic INR monitoring platforms to support decentralized diagnostics, faster anticoagulation monitoring, and workflow optimization across ICUs, ambulatory settings, and emergency care.
01 The point-of-care coagulation testing devices market forecasts increasing investment activities to support innovation in rapid diagnostics, decentralized patient monitoring, and AI-enabled coagulation analysis technologies. Companies are focusing on expanding portable testing capabilities, strengthening hospital and homecare diagnostic infrastructure, and accelerating development of connected coagulation monitoring platforms. Following are some major funding and investment activities undertaken by companies in 2025:
02 Key Investment and Funding Activities in Point-of-Care Coagulation Testing Devices Market, 2025 Company Recent Activity Timeline Focus Value HemoSonics Growth Funding September 2025 HemoSonics secured growth financing to accelerate development of advanced viscoelastic point-of-care coagulation diagnostic platforms and expand hospital-based critical care testing infrastructure. USD 5 Million CoaguSense Strategic Investment March 2026 CoaguSense expanded investments in connectivity-focused and AI-enabled point-of-care coagulation monitoring technologies to strengthen decentralized anticoagulation management and home-based testing capabilities. Undisclosed
01 Rising Demand for Rapid Bedside Coagulation Assessment and Expanding Use of Anticoagulant Therapies Drives Market The increasing burden of trauma cases, cardiovascular emergencies, and critical care admissions is significantly driving demand for point-of-care coagulation testing devices across hospitals and emergency departments. These systems enable rapid clotting assessment, support immediate anticoagulation management, and reduce dependence on centralized laboratory workflows during time-sensitive interventions. Growing utilization in operating rooms, intensive care units, and ambulatory surgical centers is accelerating adoption of portable analyzers capable of delivering faster decision-making and streamlined patient monitoring, thereby significantly driving point-of-care coagulation testing devices market growth.The expanding global use of anticoagulant therapies for atrial fibrillation, deep vein thrombosis, and cardiac disorders is further increasing demand for decentralized coagulation monitoring technologies. Point-of-care systems are increasingly utilized for routine INR monitoring, personalized dose management, and home-based coagulation assessment to improve patient convenience and treatment continuity. Rising preference for connected healthcare infrastructure and portable diagnostic workflows is strengthening market expansion globally. For example, Roche continues expanding digital coagulation monitoring integration within decentralized anticoagulation management.
01 Variability in Hematocrit Levels Interfering with POC and High Susceptibility of Point-of-Care Coagulation Devices Restrain Market A major restraint in the point-of-care coagulation testing devices market is the impact of abnormal hematocrit levels on testing accuracy during critical care and anticoagulation monitoring. Variations in red blood cell concentration can distort electrochemical and microfluidic clotting measurements, particularly in neonatal, anemic, and dialysis patients. This creates concerns regarding result reliability during emergency decision-making and dosage adjustments. Consequently, hospitals often require additional laboratory confirmation, limiting complete reliance on portable coagulation testing.Portable coagulation analyzers frequently face performance variability when monitoring patients receiving heparin and direct oral anticoagulant therapies during emergency and perioperative care. Drug-induced alterations in clotting pathways can interfere with rapid bedside measurements, creating inconsistencies in coagulation interpretation and anticoagulation dosage assessment. This limitation is particularly challenging in cardiac surgery, stroke management, and intensive care applications where precise coagulation monitoring is critical. Consequently, clinicians often depend on centralized laboratory confirmation, restricting broader confidence in decentralized coagulation testing adoption.
01 Expansion of Decentralized Programs and Emergence of Smartphone-connected Devices Offer Growth Opportunities for Point-of-care Coagulation Testing Devices Market Players A key point-of-care coagulation testing devices market growth opportunity across homecare and outpatient settings. Increasing preference for remote patient monitoring and reduced hospital dependency is accelerating adoption of portable INR and coagulation analyzers among patients receiving long-term anticoagulant therapy. Healthcare systems are increasingly supporting connected coagulation monitoring infrastructure to improve treatment continuity and reduce emergency complications. For example, Roche continues strengthening digital self-testing ecosystems for decentralized coagulation monitoring and remote anticoagulation management.The growing development of smartphone-connected point-of-care coagulation testing devices is creating new opportunities for remote anticoagulation management and decentralized patient monitoring. These compact systems integrate wireless connectivity, mobile health applications, and cloud-based data sharing to enable real-time INR tracking outside traditional clinical environments. Demand is increasing among homecare providers and chronic anticoagulation patients seeking convenient self-testing solutions with automated physician reporting capabilities. For example, CoaguSense is advancing connected portable coagulation monitoring technology supporting digital home-based coagulation management.
01 Limited Shelf Stability of Disposable Tests and Risk of Sample Clot Formation Challenges Point-of-Care Coagulation Testing Devices Market Growth Disposable coagulation testing cartridges often require tightly controlled temperature and humidity conditions to preserve reagent stability and diagnostic accuracy during storage and transport. Environmental fluctuations in ambulances, military healthcare units, and remote clinics can compromise cartridge performance and reduce testing reliability during critical coagulation assessment. Short usability periods also increase consumable wastage and inventory replacement frequency for healthcare providers. These operational and logistical limitations continue restricting broader deployment of portable coagulation analyzers.Premature microclot formation in blood samples before cartridge processing remains a critical challenge in the point-of-care coagulation testing devices market, particularly during emergency and high-volume clinical workflows. Delays in sample application, improper handling, or inadequate mixing can alter clotting parameters and generate inaccurate bedside results. This issue is especially problematic in trauma units and operating rooms where rapid testing turnaround is essential. Consequently, repeat testing requirements increase consumable usage and operational burden across acute care settings.
June 2026 Abbott expanded its point-of-care diagnostics portfolio with advancements in coagulation testing technologies. The company focused on improving rapid blood coagulation assessment, workflow efficiency, and clinical decision-making in emergency and surgical care settings.
March 2026 Siemens Healthineers expanded its point-of-care testing solutions with enhanced coagulation monitoring technologies. The developments support faster testing, improved patient management, and integration of diagnostic data across healthcare environments.
January 2026 Werfen expanded its hemostasis diagnostics portfolio with new point-of-care coagulation testing solutions. The company focused on advancing rapid testing capabilities for operating rooms, critical care units, and emergency departments.
October 2025 Roche expanded its diagnostics portfolio with improvements in coagulation monitoring and decentralized testing solutions. The initiatives support healthcare providers in delivering faster and more efficient blood coagulation assessments.